Blood Cancer Journal Contents: 31 Aug 2022

The latest content from Blood Cancer Journal: 31 August 2022

Determining drug dose in the era of targeted therapies: playing it (un)safe? Sigrid S. Skånland & Geir E. Tjønnfjord Review Article | 23 August 2022 | Article number: 123 |  doi: 10.1038/s41408-022-00720-7

Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy Kelsey M. Frechette, Scott C. Lester [...] Nadia N. Laack Correspondence | 22 August 2022 | Article number: 121 |  doi: 10.1038/s41408-022-00711-8

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation Ruth Meier, Gabriele Greve [...] Michael Lübbert Article | 22 August 2022 | Article number: 122 |  doi: 10.1038/s41408-022-00715-4

Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster Rachel Zeig-Owens, David G. Goldfarb [...] Ola Landgren Article | 22 August 2022 | Article number: 120 |  doi: 10.1038/s41408-022-00709-2

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group Andrea Havasi, Cihan Heybeli [...] Heather Landau Article | 18 August 2022 | Article number: 119 |  doi: 10.1038/s41408-022-00714-5

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia François Vergez, Laetitia Largeaud [...] Christian Récher Article | 16 August 2022 | Article number: 117 |  doi: 10.1038/s41408-022-00712-7

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation Hailin Chen, Tengteng Yu [...] Yu-Tzu Tai Article | 16 August 2022 | Article number: 118 |  doi: 10.1038/s41408-022-00716-3

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis Giacomo Coltro, Francesco Mannelli [...] Paola Guglielmelli Article | 12 August 2022 | Article number: 116 |  doi: 10.1038/s41408-022-00713-6

Venetoclax ex vivo functional profiling predicts improved progression-free survival Vikas A. Gupta, Shannon M. Matulis [...] Lawrence H. Boise Correspondence | 04 August 2022 | Article number: 115 |  doi: 10.1038/s41408-022-00710-9

Journal Info Submit Manuscript RSS Feed

This email has been sent to ignoble.experiment@arconati.us by Blood Cancer Journal.

Unsubscribe Manage Alerts Privacy policy Contact us

Springer Nature Limited is a company registered in England and Wales under Company Number 785998 with its registered office at The Campus, 4 Crinan Street, London, N1 9XW, United Kingdom

Nature is part of Springer Nature. © 2022 Springer Nature Limited. All rights reserved.